Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Nov 13, 2016 9:30 AM - Nov 15, 2016 5:30 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

13th DIA Japan Annual Meeting 2016

[V1-S3] What is the Goal of Patient-Engaged Drug Development?

Session Chair(s)

Kaori  Muto, PhD

Kaori Muto, PhD

Professor, Department of Public Policy, The Institute of Medical Science

The University of Tokyo, Japan

The idea that medical treatment and drug development is something only for doctors and pharmaceutical companies is becoming a thing of the past. While many people have been working on realizing drug development that meets real patients’ needs through this enhanced, patient-engaged approach, concerns remain about whether the challenges of this goal are properly aligned among stakeholders. This session will discuss the goal of patient-engaged drug development with panelists from patient, academia, and industry sides, including what is needed to create greater value for patients as well as for those stakeholders who support the patient-engaged approach.

Speaker(s)

Satoshi  Miki

Industry’s Perspective on “Patient Engagement”

Satoshi Miki

UCB Japan Co., Ltd., Japan

Senior Advisor

Haruka  Nakada, JD, PhD

"Patient Engagement" from the Ethics Point of View

Haruka Nakada, JD, PhD

The Institute of Medical Science, The University of Tokyo, Japan

Project Research Fellow, Department of Public Policy, Human Genome Center

Ikuko  Yamaguchi

Patient’s Perspective on “Patient Engagement”

Ikuko Yamaguchi

NPO COML, Japan

Board Chairperson

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.